Key facts
- This page summarizes Charity Scripture's Form 3 filing for BELLICUM PHARMACEUTICALS, INC.
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 02 Dec 2021, 14:21.
Charity Scripture - 01 Dec 2021 Form 3 Insider Report for BELLICUM PHARMACEUTICALS, INC
- Reporting relationship
- Chief Development Officer
- Issuer ticker
- N/A
- Reported as of
- 01 Dec 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 02 Dec 2021, 14:21:48 UTC
- Next SEC filing
- 16 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- Charity Scripture
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Charity Scripture filed Form 3 for BELLICUM PHARMACEUTICALS, INC on 02 Dec 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BLCM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 14,587
- Date
- 01 Dec 2021
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BLCM
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,500
- Exercise price
- $4.41
- Footnotes
- F1
BLCM
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,300
- Exercise price
- $1.36
- Footnotes
- F2
BLCM
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $7.13
- Footnotes
- F3
BLCM
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,000
- Exercise price
- $2.97
- Footnotes
- F4
BLCM
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $2.88
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
25% of the shares subject to the stock option vest and became exercisable on October 1, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
Footnote F2
25% of the shares subject to the stock option vest and became exercisable on February 3, 2021, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
Footnote F3
100% of the shares subject to the stock option vest and became exercisable on August 3, 2021.
Footnote F4
50% of the shares subject to the stock option vest and become exercisable on December 15, 2021, and the remaining shares subject to the stock option vest and become exercisable in 12 equal monthly installments thereafter.
Footnote F5
50% of the shares subject to the stock option vest and become exercisable on August 16, 2022, and the remaining shares subject to the stock option vest and become exercisable in 12 equal monthly installments thereafter.